MAIA Biotechnology Files 8-K: Material Agreement & Equity Sales
Ticker: MAIA · Form: 8-K · Filed: Apr 23, 2024 · CIK: 1878313
| Field | Detail |
|---|---|
| Company | Maia Biotechnology, INC. (MAIA) |
| Form Type | 8-K |
| Filed Date | Apr 23, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $2, $664,994, $2.034, $340,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
MAIA Bio inked a big deal and sold some stock, filing it all today.
AI Summary
MAIA Biotechnology, Inc. announced on April 22, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events, including financial statements and exhibits. The filing was made on April 23, 2024.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- April 22, 2024 (date) — Date of earliest event reported
- April 23, 2024 (date) — Filing date
- 001-41455 (other) — SEC File Number
FAQ
What is the nature of the material definitive agreement entered into by MAIA Biotechnology, Inc.?
The filing states that MAIA Biotechnology, Inc. entered into a material definitive agreement on April 22, 2024, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold unregistered?
The filing mentions 'Unregistered Sales of Equity Securities' as an item of disclosure, but the specific type and amount of equity securities sold are not detailed in the provided text.
What are the 'Other Events' reported in this 8-K filing?
The filing lists 'Other Events' as a category of information, but the specific events are not elaborated upon in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on April 22, 2024.
What is MAIA Biotechnology, Inc.'s principal executive office address?
MAIA Biotechnology, Inc.'s principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
Filing Stats: 1,310 words · 5 min read · ~4 pages · Grade level 13 · Accepted 2024-04-23 16:05:55
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share (" Common Stock "), and (ii)
- $2 — f Common Stock, at a price per share of $2.034, for an aggregate purchase price of
- $664,994 — gregate purchase price of approximately $664,994. The Warrants are exercisable at a pri
- $2.034 — e " Warrants ") at a price per share of $2.034 for an aggregate purchase price of appr
- $340,000 — gregate purchase price of approximately $340,000 The Director Warrants are exercisable a
- $2.26 — Warrants are exercisable at a price of $2.26 per share, which price represents the g
- $300,000 — gregate purchase price of approximately $300,000 and Company director Louie Ngar Yee sub
- $40,000 — gregate purchase price of approximately $40,000. The Shares and the Warrants (and the
- $1.0 m — ferings is expected to be approximately $1.0 million, prior to deducting offering expe
Filing Documents
- d815817d8k.htm (8-K) — 34KB
- d815817dex41.htm (EX-4.1) — 84KB
- d815817dex42.htm (EX-4.2) — 72KB
- d815817dex101.htm (EX-10.1) — 328KB
- d815817dex991.htm (EX-99.1) — 9KB
- 0001193125-24-106975.txt ( ) — 794KB
- maia-20240422.xsd (EX-101.SCH) — 3KB
- maia-20240422_lab.xml (EX-101.LAB) — 18KB
- maia-20240422_pre.xml (EX-101.PRE) — 11KB
- d815817d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 4.1 Form of Investor Warrant 4.2 Form of Director Warrant 10.1* Form of Securities Purchase Agreement 99.1 Press Release dated April 23, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * The schedules (and similar attachments) to this exhibit have been omitted from this filing pursuant to Item 601(b)(10) of Regulation S-K. The Company agrees to furnish a supplemental copy of any omitted schedule (or similar attachment) to the Securities and Exchange Commission upon request. 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 23, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 4